Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...

Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...

Objectives To evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still’s ...

Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...

Objective To assess prevalence, associated disability and pain burden of the main rheumatic and musculoskeletal diseases ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...

Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...

Over the last decade, the outlook for patients with rheumatoid arthritis (RA) has improved, but there is growing interest in ...

Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) ...

Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...

Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial ...

Background Psoriatic arthritis (PsA) is a multifaceted condition with a broad spectrum of manifestations and a range of associated comorbidities. A notable segment of patients with PsA remains ...